[HTML][HTML] Dacomitinib for advanced non-small cell lung cancer patients harboring major uncommon EGFR alterations: a dual-center, single-arm, ambispective cohort …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu, T Zhang… - Frontiers in …, 2022 - frontiersin.org
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu… - Frontiers in …, 2022 - europepmc.org
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
[HTML][HTML] Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …
[引用][C] Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective …
HS Li, GJ Yang, Y Cai, JL Li, HY Xu… - Frontiers in …, 2022 - jglobal.jst.go.jp
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major
Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in …
Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in …